TSBX insider filings
Turnstone Biologics Corp. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-08-12. Screen TSBX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TSBX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Turnstone Biologics Corp.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-08-12 | 4 | Versant Ventures V, LLC — 10% owner Versant Venture Capital V, L.P. — 10% owner Versant Ophthalmic Affiliates I, L.P. — 10% owner Versant Affiliates Fund V, L.P. — 10% owner Versant Ventures V GP-GP (Canada), Inc. — 10% owner Versant Ventures V (Canada), L.P. — 10% owner Versant Venture Capital V (Canada), LP — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II, L.P. — 10% owner | Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006 · Code (U): 274,990 | EDGAR |
| 2025-08-12 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director | Code (U): 3,099,265 | EDGAR |
| 2025-08-08 | 4 | Jerel Davis — Director | Code (U): 274,990 · Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006 | EDGAR |
| 2025-08-08 | 4 | Gupta Rishi — Director | Code (U): 3,099,265 | EDGAR |
| 2024-07-02 | 4 | Rajangam Kanya — Director | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Jerel Davis — Director, 10% owner | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Gould Robert J — Director | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Waddill William D. — Director | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Gupta Rishi — Director, 10% owner | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2024-04-16 | 4 | Waddill William D. — Director | Grant/award (A): 25,540 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | FMR LLC | Holdings only — no transactions reported | EDGAR |
| 2023-10-17 | 4 | Ramanan Venkat — Chief Financial Officer | Grant/award (A): 46,606 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Rajangam Kanya — Director | Grant/award (A): 8,012 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Campisi Peter Joseph Jr. — Chief Legal Officer | Grant/award (A): 44,377 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Burgess Michael F. — Interim Chief Medical Officer, Director | Grant/award (A): 11,464 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Azmat Saryah — Chief Business Officer | Grant/award (A): 56,637 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Farah Sammy J. — President & CEO, Director | Grant/award (A): 155,321 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Jerel Davis — Director, 10% owner | Grant/award (A): 25,540 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | ABBOT STEWART — Chief Scientific Officer | Grant/award (A): 45,542 (derivative) @ $0 | EDGAR |
| 2023-10-17 | 4 | Gupta Rishi — Director, 10% owner | Grant/award (A): 25,540 (derivative) @ $0 | EDGAR |
| 2023-07-27 | 4 | FMR LLC — 10% owner | Conversion (C): 91,663 · Conversion (C): 106,496 · Conversion (C): 150,809 · Conversion (C): 483,684 · Conversion (C): 296,396 · Conversion (C): 4,939 · +6 more | EDGAR |
| 2023-07-27 | 4 | Jerel Davis — Director, 10% owner | Conversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 more | EDGAR |
| 2023-07-27 | 4 | Versant Ventures V, LLC — 10% owner Versant Venture Capital V, L.P. — 10% owner Versant Ophthalmic Affiliates I, L.P. — 10% owner Versant Affiliates Fund V, L.P. — 10% owner Versant Ventures V GP-GP (Canada), Inc. — 10% owner Versant Ventures V (Canada), L.P. — 10% owner Versant Venture Capital V (Canada), LP — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II, L.P. — 10% owner | Conversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 more | EDGAR |
| 2023-07-24 | 4 | Gupta Rishi — Director, 10% owner | Conversion (C): 2,682,599 · Purchase (P): 416,666 @ $12 · Conversion (C): 937,372 (derivative) · Conversion (C): 1,249,829 (derivative) · Conversion (C): 266,240 (derivative) · Conversion (C): 229,158 (derivative) | EDGAR |
| 2023-07-24 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VI LLC — Director, 10% owner | Conversion (C): 2,682,599 · Purchase (P): 416,666 @ $12 · Conversion (C): 937,372 (derivative) · Conversion (C): 1,249,829 (derivative) · Conversion (C): 266,240 (derivative) · Conversion (C): 229,158 (derivative) | EDGAR |
Recent 8-K events — Turnstone Biologics Corp.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-08-11 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-17 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-01 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-01 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-11 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TSBX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs